EUCTR2006-003984-30-DE进行中（未招募）不适用
A multicenter, randomized, double-blind, two-arm, vehicle-controlled, parallel-group, two stage study to evaluate and demonstrate the efficacy and to evaluate the safety of pimecrolimus 1% cream in the treatment of seborrhoeic dermatitis in patients 12 years of age and older
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 690
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Male or female patients aged 18 years or older
- •- Patients, who have
- •- mild, moderate or severe seborrhoeic dermatitis with (overall IGA 1-3) and
- •- at least mild lesional erythema and at least mild scaling of non-scalp skin
- •- Written informed consent (by a legal guardian for patients below the age of consent)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •- Patients who have participated in Stage A cannot be recruited in Stage B.
- •Concurrent diseases/conditions and history of other diseases/conditions
- •- Presence of any concurrent dermatological condition in the affected area that according to the investigator may interfere with the clinical evaluation (such as acne, rosacea, pityriasis versicolor, psoriasis, lupus erythematosus, scleroderma, active skin infection).
- •- Known HIV infection or history of immunocompromised status (e.g. lymphoma, AIDS,
- •Wiskott-Aldrich syndrome) or known immunosuppression.
- •- History or presence of malignancy of any organ system or lymphoproliferative diseases or pre-malignant skin condition (such as actinic keratosis).
- •Other medications / therapies
- •- Application of topical corticosteroids or other topical medication (including nonprescription products or medicated shampoos) known to influence seborrhoeic dermatitis (such as antifungals, lithium succinate/gluconate, calcipotriol/calcipotriene, tacrolimus, pimecrolimus) within 7 days prior to the first application of study medication.
- •- Administration of any systemic immunosuppressant (such as systemic corticosteroids, systemic tacrolimus, cyclosporine) or phototherapy (e.g. UVB, PUVA within 30 days or 5 half-lives of enrollment, whichever is longer, prior to drug application.
- •- Administration of any systemic medication (including non-prescription products) known or suspected to have a positive or negative effect on seborrhoeic dermatitis (such as oral antifungals, lithium salts) within 30 days or 5 half-lives of enrollment, whichever is longer, prior to drug application.
- •Investigational drug / therapy use
- •- Use of any investigational drugs at the time of enrollment, or within 30 days or 5 halflives of enrollment, whichever is longer.
- •- Ingredient hypersensitivity
- •- Known serious adverse reactions or hypersensitivity to pimecrolimus, or any ingredients of pimecrolimus cream.
- •Compliance / reliability / investigator’s judgment
- •- Patients who are in the opinion of the investigator known to be unreliable, or noncompliant, or with any condition or prior or present treatment (including cosmetic products) rendering the patient ineligible for the study.
- •- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (> 5 mIU/ml).
- •- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, including women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner and women whose partners have been sterilized by vasectomy or other means, UNLESS
- •1) Patients meet the following definition of post-menopausal:
- •12 months of natural (spontaneous) amenorrhea
- •6 months of spontaneous amenorrhea with serum FSH levels >40 mIU/m
- •6 weeks post surgical bilateral oophorectomy with or without hysterectomy
- •2) Patients are using one or more of the following acceptable methods of contraception:
- •Surgical sterilization (e.g., bilateral tubal ligation, hysterectomy)
- •Hormonal contraception (implantable, patch, oral)
- •Double-barrier methods (any double combination of: male or female condom with
- •spermicidal gel, diaphragm, sponge, cervical cap)
- •Any combination of IUD and a barrier method.
- •Since the known reproductive and developmental toxicity profile of pimecrolimus is low, acceptable methods of contrac
研究者
相似试验
Unknown
不适用
TurmXtra 60N (Water dispersible Turmeric extract) capsule 250 mg in subjects with Non Alcoholic Fatty Liver Disease (NAFLD)CTRI/2020/03/023814Inventia Healthcare Limited India
进行中（未招募）
1 期
Sodium Alginate Chewable Tablet European Symptom Relief Study for patients with symptoms of GORDGastro-Oesophageal Reflux Disease (GORD)MedDRA version: 20.1Level: LLTClassification code 10018203Term: GERDSystem Organ Class: 100000004856EUCTR2014-005261-69-ITRECKITT BENCKISER HEALTHCARE (UK) LIMITED424
进行中（未招募）
不适用
Gaviscon® Double Action Mint as add-on therapy in GORD patients with inadequate response to PPI treatmentPatients with Gastro Oesophageal Reflux Disease (GORD) with inadequate response to PPI treatmentEUCTR2012-004470-25-GBReckitt Benckiser Healthcare (UK) Ltd
进行中（未招募）
不适用
Study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate response to once daily proton pump inhibitor treatment.Gastro Oesophageal Reflux Disease (GORD)MedDRA version: 17.1Level: LLTClassification code 10066874Term: Gastroesophageal reflux diseaseSystem Organ Class: 100000004856EUCTR2011-005486-21-DEReckitt Benckiser Healthcare (UK) Ltd.150
进行中（未招募）
1 期
Study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate response to once daily proton pump inhibitor treatment.Gastro Oesophageal Reflux Disease (GORD)MedDRA version: 15.1Level: LLTClassification code 10066874Term: Gastroesophageal reflux diseaseSystem Organ Class: 100000004856EUCTR2011-005486-21-DKReckitt Benckiser Healthcare (UK) Ltd.150